Michael Lenardo

Chief
Molecular Development of the Immune System Section
Laboratory of Immunology
United States of America

Scientist Immunology
Biography

Dr. Lenardo graduated with a B.A. from the Johns Hopkins University and an M.D. from Washington University, St. Louis. He performed clinical work in internal medicine and research at the University of Iowa and received postdoctoral training at the Whitehead Institute for Biomedical Research at the Massachusetts Institute of Technology. He established an independent research unit in the Laboratory of Immunology in 1989 and became a senior investigator and section chief in 1994. Dr. Lenardo serves on several editorial boards and has given numerous lectures around the world on his work on the molecular regulation of immune homeostasis. His work focuses on lymphocyte apoptosis, autoimmunity, and genomics of the immune system. He was one of the founders of the NIH-Oxford-Cambridge Scholars program for doctoral training and the NIH M.D./Ph.D. partnership program.

Research Intrest

Genetic diseases of immune homeostasis and autoimmunity

List of Publications
Baltimore D, Sen R, Sharp PA, Singh H, Staudt L, Lebowitz JH, Baldwin Jr AS, Clerc RG, Corcoran LM, Baeuerle PA, Lenardo MJ, inventors. Nuclear factors associated with transcriptional regulation. United States patent US 6,410,516. 2002 Jun 25.
Nye SH, Lenardo MJ, Mcfarland HF, Matis LA, Mueller EE, Mueller JP, Pelfrey CM, Squinto SP, Wilkins JA, inventors; The United States Of America As Represented By The Department Of Health, Human Services, assignee. Modified myelin basic protein molecules. United States patent US 7,041,503. 2006 May 9.
Baehrecke EH, Alva A, Lenardo MJ, Li Y, inventors; University of Maryland College Park, National Institutes Of Health, assignee. Function of autophagy genes in cell death. United States patent US 7,838,645. 2010 Nov 23.
Lenardo MJ, Chan FK, Siegel RM, inventors; The United States Of America As Represented By The Department Of Health, Human Services, assignee. Identification of a novel domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function. United States patent US 7,148,061. 2006 Dec 12.